Taiho Pharmaceutical Company Ltd.
47 articles about Taiho Pharmaceutical Company Ltd.
-
Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical, has pumped up its venture capital pool from $50 million to $300 million. It also indicates it plans to accelerate its “open innovation” through the investments.
-
Taiho Oncology Presents Real-World Adherence Data for LONSURF® (trifluridine and tipiracil) in Metastatic Colorectal Cancer at ASCO Quality of Care Symposium
9/28/2018
Taiho Oncology today announced real-world adherence data for patients with metastatic colorectal cancer (mCRC) who were treated with LONSURF® (trifluridine and tipiracil) or Stivarga® (regorafenib).*
-
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
7/12/2018
Arcus Biosciences, Inc. announced that Taiho Pharmaceutical Co., Ltd. exercised its option under the Option and License Agreement entered into in September 2017 (Taiho Agreement) to obtain an exclusive development and commercialization license to the Company’s adenosine receptor antagonist program
-
Bay Area Startup Arcus Biosciences Lands $307 Million+ Deal With Taiho Pharma
9/21/2017
-
X-Chem Announces Multi-Target Drug Discovery Collaboration With Taiho Pharma Using DEX Technology
12/20/2016
-
Taiho Pharma Forms Venture Arm in California to Foster Cancer Biotech Start-ups
5/10/2016
-
Taiho Pharma Release: Patients With Advanced Metastatic Colorectal Cancer In Europe Now Have New Treatment Option As LONSURF (Trifluridine/Tipiracil) Receives EU Approval
4/28/2016
-
Taiho Pharma's TAS-102 Meets Primary Endpoint Of Improving Overall Survival In Phase III TERRA Study In Asian Patients With Refractory Metastatic Colorectal Cancer
4/1/2016
-
Servier, Taiho Pharma Strike $130 Million+ Cancer Pact
6/15/2015
-
Taiho Pharmaceutical Submits TAS-102 Marketing Authorisation Application To The European Medicines Agency For The Treatment Of Refractory Metastatic Colorectal Cancer
3/2/2015
-
Taiho Pharmaceutical Invests US $30 Million In Remiges Biopharma Fund, LP
7/23/2014
-
Taiho Pharmaceutical's Lonsurf® (Trifluridine And Tipiracil Hydrochloride) Tablets Approved In Japan For Treatment Of Advanced Metastatic Colorectal Cancer
3/24/2014
-
Response Genetics, Inc. Renews Agreement With Taiho Pharmaceutical to Provide Molecular Analyses for Cancer
7/17/2013
-
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
2/27/2013
-
Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
5/31/2012
-
Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102
7/25/2011
-
Taiho Pharmaceutical's Teysuno(TM) (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer
3/15/2011
-
Taiho Pharmaceutical: Teysuno(TM) (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
12/17/2010
-
Taiho Pharmaceutical Selects Medidata Solutions, Inc. Rave for Global Trials
7/28/2008
-
Taiho Pharmaceutical and Sanofi-Aventis (France) Release: S-1, a Novel Oral Fluoropyrimidine, When Combined With Cisplatin, Demonstrates Significant Improvement in Overall Survival of Advanced Gastric Cancer Patients Over S-1 Alone
6/4/2007